jRCT2051210117进行中（未招募）不适用
A multicenter, single-arm, clinical trial of adrenomedullin for cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)
未提供0 个研究点目标入组 60 人开始时间: 2022年1月6日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 60
- 主要终点
- Cerebral blood flow change rate
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Single Arm Study
- 干预模型
- Single Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 20age old over 至 90age old not（—）
- 性别
- All
入选标准
- •Patients who have given written informed consent from the patient or the sponsor to participate in the clinical trial
- •Patients aged between 20 and 90 at the time of obtaining consent
- •Patients diagnosed as CADASIL after confirming NOTCH3 gene mutation by genetic testing
- •Patients with Mini-mental state examination-J score of 10-27 or Trail maiking test score (age ajustment) of average + 1.5 SD (standard deviation) or higher
排除标准
- •Patients who cannot perform cognitive function tests (deafness, blindness, etc., MMSE-J less than 10 points
- •Severe cognitive impairment, etc.)
- •Patients received reatment with prohibited drugs or prohibited therapy within the past 12 weeks from the time of registration
- •Patients who started to take concomitant restriction drugs or changed dosage of concomitant restriction drugs within the past 4 weeks from the time of registration
- •Patients whose Mini-mental state examination-J with 4 or more points improvements between the time of registration and 4 weeks or more at the time of screening (If patients who take concomitant restriction drugs)
- •Patients with active infections requiring antibiotic treatment at registration
- •Patients with a disability equivalent to modified Rankin Scale 5 at registration
- •Patients with severe consciousness impairment (Japan Coma Scale 100 or more)
- •Patients with severe renal impairment (estimated GFR less than 30 mL / min / 1.73m2) at registration
- •Patients with severe liver damage (transaminase AST (GOT) or ALT (GPT) 100 IU / L or more) at registration
- •Patients diagnosed as having cerebral infarction or intracranial hemorrhage or transient ischemic attack or cerebral aneurysm with high probability of rupture within the last 12 weeks from the time of registration
- •Patients with occlusion or severe stenosis of the intracranial main artery or carotid artery at the time of registration
- •Patients with significant ECG abnormalities (atrioventricular block of 2-3 degrees, extension of QRS interval of 120 ms or more, extension of QTcB of 450 msec or more) at registration, or past histroy of acute coronary syndrome or acute heart failure within the last 12 weeks from the time of registration
- •Patients with systolic blood pressure less than 100 mmHg at registration
- •Patients whose pulse rate is less than 45 beats / minute or 120 beats / minute or more at registration
- •Patients with substance abuse or alcoholism
- •Patients who cannot perform MRI
- •Patients with active solid malignant tumors
- •Patients who do not give consent to contraception from the date of obtaining consent until the end of the safety evaluation period
- •Pregnant, lactating, and possibly pregnant
- •Patient who participated in another trial within 24 weeks before registration
- •Other patients judged by the Investigator or Investigator to be ineligible for this study
结局指标
主要结局
Cerebral blood flow change rate
时间窗: 28 days post adrenomedullin administration
evaluated by arterial spin labeling (Frontal lobe)
次要结局
- Serious adverse event
- Cerebral blood flow change rate (Frontal lobe)(28 days post adrenomedullin administration)
- Cerebral blood flow change rate (Whole brain mean and each area)(8 hours/15 days/28 days/90 days/180 days post adrenomedullin administration)
- Mean diffusivity change rate of the white matter (Whole brain mean and each area)(8 hours/15 days/28 days/90 days/180 days post adrenomedullin administration)
- Fractional anisotropy change rate of the white matter (Whole brain mean and each area)(8 hours/15 days/28 days/90 days/180 days post adrenomedullin administration)
研究者
相似试验
已完成
1 期
Continuous intravenous adrenomedullin therapy for patients with inflammatory bowel disease (ulcerative colitis and Crohn's disease)inflammatory bowel disease (ulcerative colitis and Crohn's disease)JPRN-UMIN000021421First Department of Internal Medicine, Faculty of Medicine, University of Miyazaki10
已完成
1 期
Multiple-dose administration study of adrenomedulliJPRN-jRCT2080224807niversity of MIyazaki12
招募中
不适用
ROCK inhibitor (ripasudil)-Alpha2 adrenoceptor agonist (brimonidine) fixed-dose combination ophthalmic solution v.s. Beta-blocker (timolol)-Carbonic anhydrase inhibitor (dorzolamide) fixed-dose combination ophthalmic solution comparison study on intraocular pressure lowering efficacy (ROCK-ABC study)jRCTs031240193114
已完成
1 期
Single-dose administration study of adrenomedulliJPRN-jRCT2080224808niversity of Miyazaki24
招募中
Unknown
sing a blood test Adrenomedullin to predict disease severity andoutcome in patients with fever presenting to Emergency DepartmentCTRI/2023/07/054779Manipal Centre for Infectious Diseases (MACID)